Stomach cancer is more prevalent in Asian countries such as China, South Korea and Japan, where it is diagnosed in 50 out of every 100,000 people and is the second most common cancer-related death, with over 900,000 new diagnoses and 800,000 deaths each year. Early diagnosis of gastric cancer is difficult because most patients do not show symptoms in the early stages. Approximately 50% of gastric cancer patients are diagnosed at a late stage. Patients with advanced stage only have an average survival time of 10-12 months. Advanced gastric cancer is a devastating disease for which there is basically no cure. Reducing the incidence and improving the chances of survival for gastric cancer patients requires more innovative and effective treatments in medical care. Trastuzumab (Herceptin, Herceptin) is known to be a breakthrough drug for the treatment of HER-2 positive breast cancer. Approximately 20-25% of gastric cancers are HER-2-positive, a number close to breast cancer. 2009 ASCO meeting reported the results of the ToGA study for HER2-positive progressive gastric cancer. The study was an open international multicenter study that included 130 centers in 24 countries. The combination of Herceptin increased the remission rate (CR) of chemotherapy drugs from 34.5% to 47.3% (in gastric cancer, the typical remission rate of chemotherapy drugs is around 30%), prolonged survival by an average of 2.7 months in patients with HER-2-positive gastric cancer, and reduced the risk by 26% compared to patients without the combination Herceptin chemotherapy regimen. Subgroup analyses showed an even greater benefit for patients with high levels of HER2-positive gastric cancer, who lived up to 16 months longer and had an average 35% lower risk of death. Thus, Herceptin is the first targeted biologic to show an overall survival advantage (os) in gastric cancer, offering a new treatment option for progressive gastric cancer.